Search

Your search keyword '"Frazao, Mateus"' showing total 2 results
Start Over Author "Frazao, Mateus"
2 results on '"Frazao, Mateus"'

1. Salmon-IgM Functionalized-PLGA Nanosystem for Florfenicol Delivery as an Antimicrobial Strategy against Piscirickettsia salmonis.

Author

Velásquez, Felipe, Frazao, Mateus, Diez, Arturo, Villegas, Felipe, Álvarez-Bidwell, Marcelo, Rivas-Pardo, J. Andrés, Vallejos-Vidal, Eva, Reyes-López, Felipe, Toro-Ascuy, Daniela, Ahumada, Manuel, and Reyes-Cerpa, Sebastián

Subjects
*ATLANTIC salmon, *SALMON farming, *SURFACE charges, *IMPACT loads, *CONFOCAL microscopy
Abstract

Salmonid rickettsial septicemia (SRS), caused by Piscirickettsia salmonis, has been the most severe health concern for the Chilean salmon industry. The efforts to control P. salmonis infections have focused on using antibiotics and vaccines. However, infected salmonids exhibit limited responses to the treatments. Here, we developed a poly (D, L-lactide-glycolic acid) (PLGA)-nanosystem functionalized with Atlantic salmon IgM (PLGA-IgM) to specifically deliver florfenicol into infected cells. Polymeric nanoparticles (NPs) were prepared via the double emulsion solvent-evaporation method in the presence of florfenicol. Later, the PLGA-NPs were functionalized with Atlantic salmon IgM through carbodiimide chemistry. The nanosystem showed an average size of ~380–410 nm and a negative surface charge. Further, florfenicol encapsulation efficiency was close to 10%. We evaluated the internalization of the nanosystem and its impact on bacterial load in SHK-1 cells by using confocal microscopy and qPCR. The results suggest that stimulation with the nanosystem elicits a decrease in the bacterial load of P. salmonis when it infects Atlantic salmon macrophages. Overall, the IgM-functionalized PLGA-based nanosystem represents an alternative to the administration of antibiotics in salmon farming, complementing the delivery of antibiotics with the stimulation of the immune response of infected macrophages. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)

Author

Universidad de Sevilla. Departamento de Geografía Física y Análisis Geográfico Regional, Universidad de Sevilla. Departamento de Psiquiatría, Garrido Cumbrera, Marco, Marzo Ortega, Helena, Christen, Laura, Plazuelo Ramos, Pedro, Webb, Dale, Jacklin, Clare, Irwin, Shantel, Grange, Laurent, Makri, Souzi, Frazao Mateus, Elsa, Mingolla, Serena, Antonopoulou, Katy, Sanz Gómez, Sergio, Correa Fernández, José, Carmona, Loreto, Navarro Compán, Victoria, Universidad de Sevilla. Departamento de Geografía Física y Análisis Geográfico Regional, Universidad de Sevilla. Departamento de Psiquiatría, Garrido Cumbrera, Marco, Marzo Ortega, Helena, Christen, Laura, Plazuelo Ramos, Pedro, Webb, Dale, Jacklin, Clare, Irwin, Shantel, Grange, Laurent, Makri, Souzi, Frazao Mateus, Elsa, Mingolla, Serena, Antonopoulou, Katy, Sanz Gómez, Sergio, Correa Fernández, José, Carmona, Loreto, and Navarro Compán, Victoria

Abstract

Aim To assess the impact of the COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases (RMDs). Methods REUMAVID is a cross-sectional study using an online survey developed by an international multidisciplinary patient-led collaboration across seven European countries targeting unselected patients with RMDs. Healthcare access, daily activities, disease activity and function, well-being (WHO Five Well-Being Index (WHO-5)), health status, anxiety/depression (Hospital Anxiety and Depression Scale (HADS)) and access to information were evaluated. Data were collected in April–July 2020 (first phase). Results Data from the first phase included 1800 patients with 15 different RMDs (37.2% axial spondyloarthritis, 29.2% rheumatoid arthritis, 17.2% osteoarthritis and others). Mean age was 53, 80% female and 49% had undertaken university studies. During the beginning of the pandemic, 58.4% had their rheumatology appointment cancelled and 45.6% reported not having received any information relating to the possible impact of SARS-CoV-2 infection in their RMDs, with the main source being patient organisations (27.6%). Regarding habits, 24.6% increased smoking, 18.2% raised their alcohol consumption, and 45.6% were unable to continue exercising. Self-reported disease activity was high (5.3±2.7) and 75.6% reported elevated pain. Half the patients (49.0%) reported poor well-being (WHO-5) and 46.6% that their health had changed for the worse during lockdown. According to HADS, 57.3% were at risk of anxiety and 45.9% of depression. Conclusion Throughout the first wave of the COVID-19 pandemic, patients with RMDs have experienced disruption in access to healthcare services, poor lifestyle habits and negative effects on their overall health, well-being and mental health. Furthermore, information on COVID-19 has not reached patients appropriately.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results